Thesis (Ph. D.)--University of Washington, 1996. / Vita. Includes bibliographical references (leaves [128]-143).

Diss. (sammanfattning) Uppsala : Univ., 2002. / Härtill 5 uppsatser.

Orientadores: Andre Deeke Sasse, Carmen Silvia Passos Lima / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T04:20:53Z (GMT). No. of bitstreams: 1 Santos_LucasVieirados_M.pdf: 843952 bytes, checksum: bd8daf1913e68951fafe63ae91e9b070 (MD5) Previous issue date: 2013 / Resumo: Introdução: O linfoma não-Hodgkin é o sexto grupo de neoplasias em mortalidade no mundo. Quando em estágio precoce, o linfoma não-Hodgkin pode ser curado com quimioterapia. A radioterapia tem sido utilizada para se reduzir a recorrência local, entretanto o seu impacto nos desfechos de sobrevivência é desconhecido. Vários estudos tentaram responder a esta questão, mas com resultados conflitantes. Frente a resultados controversos derivados de estudos randomizados, uma revisão sistemática da literatura faz-se necessária para determinar se a radioterapia, acrescentada ao tratamento sistêmico, traz ganhos reais para o paciente. Objetivos: Comparar os desfechos do paciente com linfoma não-Hodgkin agressivo e localizado tratado com quimioterapia seguido de radioterapia, com os da quimioterapia isoladamente. Métodos: Revisão sistemática da literatura com meta-análise. Estudos clínicos randomizados no tratamento do linfoma não-Hodgkin foram identificados, através de busca nas bases de dados Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, e LILACS. Referências de artigos encontrados, Resumos de apresentações em congressos e bases de dados de estudos em andamento também foram utilizados para localizar estudos pertinentes. Critérios de inclusão: estudos controlados randomizados que compararam radioterapia adicionada ao tratamento sistêmico com tratamento sistêmico isoladamente em pacientes com linfoma não-Hodgkin agressivo e localizado. Dois revisores extraíram independentemente os dados dos artigos utilizando formulários de extração de 10 dados. Quando possível, para cada desfecho clínico foi feita meta-análise com os dados extraídos, com o fim de calcular o efeito dos tratamentos entre os estudos. Os resultados da meta-análise são expressos como Risco Relativo (RR), e Hazard Ratio (HR), com o correspondente intervalo de confiança (IC) de 95%. Os desfechos clínicos avaliados foram sobrevida global, sobrevida livre de progressão, resposta radiológica e toxicidade. O modelo de efeito fixo foi usado para se calcular as variáveis de interesse. Resultados: De um total de 7020 estudos identificados por meio da estratégia de busca, cinco foram selecionados. Destes, um estudo foi excluído. Quatro estudos, compreendendo 1796 pacientes foram incluídos na meta-análise. A adição de radioterapia trouxe incremento na sobrevivência livre de progressão [HR 0,81; IC95% 0,67-0,98; p=0,03], sem, entretanto trazer impacto na taxa de resposta ou em sobrevivência global. As diferenças em como os dados foram reportados não permitiu que os dados de segurança fossem combinados. Conclusão: Até o presente momento, não há evidência de que a radioterapia traga ganhos em sobrevivência global em pacientes com linfoma não-Hodgkin agressivo e localizado. Investigações adicionais, com a incorporação dos agentes biológicos à quimioterapia, são necessárias / Abstract: Background: Non-Hodgkin lymphoma is the sixth group of neoplasms in mortality in the world. Aggressive and localized non-Hodgkin lymphoma can be cured by chemotherapy. Radiotherapy has been used to reduce local recurrence, however its impact on survival outcomes is unknown. Several studies have attempted to answer this question, but with conflicting results. Thus, a systematic literature review is needed to determine whether radiation therapy added to systemic treatment enhances the efficacy in non-Hodgkin lymphoma treatment. Objectives: To compare outcomes of patients with aggressive and localized non- Hodgkin lymphoma treated with chemotherapy followed by radiotherapy with chemotherapy alone. Methods: This is a systematic review with meta-analysis. Randomized clinical trials were identified the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS. Inclusion criteria: randomized controlled trials that compared the addition of radiotherapy to systemic therapy versus systemic therapy alone in patients with aggressive and localized lymphoma. Two reviewers independently extracted data from articles using data extraction forms. When possible, for each clinical outcome was performed meta-analysis of the extracted data in order to calculate the effect of treatments across studies. The results of the meta-analysis are expressed as relative risk (RR) and hazard ratio (HR) with corresponding confidence interval (CI) of 95%. The main outcomes were overall 12 survival, progression-free survival, radiologic response and toxicity. The fixed-effect model was used to estimate the effect size. Results: A total of 7,020 studies identified through the search strategy, five were selected. Of these, one study was excluded. Four studies comprising 1,796 patients were included in the meta-analysis. The addition of radiotherapy increased the progression-free survival [HR 0.81, 95% CI 0.67 to 0.98, p = 0.03]. There were no differences in response rate or overall survival. The differences in how data was reported did not allow us to combine toxicity data Conclusion: To date, there is no evidence that radiotherapy will increase overall survival in patients with aggressive and localized non-Hodgkin lymphoma. Further investigations, with the incorporation of biologic agents to chemotherapy, are needed / Mestrado / Clinica Medica / Mestre em Clinica Medica

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2009. / Härtill 4 uppsatser.

Ko Kin Ming Jeffery. / Thesis submitted in: July 2005. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 99-111). / Abstracts in English and Chinese. / Acknowledgements --- p.i / Abstract --- p.ii / Table of Contents --- p.ix / List of Tables --- p.xiii / List of Figures --- p.xv / List of Abbreviations --- p.xvi / Chapter Chapter 1: --- Introduction --- p.1 / Chapter 1.1 --- Malignant Lymphoma --- p.1 / Chapter 1.2 --- Non-Hodgkin's Lymphoma --- p.1 / Chapter 1.3 --- Diffuse Large B-cell Lymphoma --- p.2 / Chapter 1.3.1 --- General Features of Diffuse Large B-cell Lymphoma --- p.2 / Chapter 1.3.2 --- Morphologic variants of Diffuse Large B-cell Lymphoma --- p.4 / Chapter 1.3.2.1 --- Centroblastic vairant --- p.5 / Chapter 1.3.2.2 --- Immunoblastic variant --- p.5 / Chapter 1.3.2.3 --- Anaplastic variant --- p.6 / Chapter 1.3.3 --- Immunophenotype of Diffuse Large B-cell Lymphoma --- p.6 / Chapter 1.3.3.1 --- Lineage-associated antigens --- p.6 / Chapter 1.3.3.1.1 --- B-cell lineage antigens --- p.6 / Chapter 1.3.3.1.2 --- T-cell lineage antigens --- p.7 / Chapter 1.3.3.2 --- Antigen involved in regulation of cell proliferation and apoptosis --- p.8 / Chapter 1.3.3.2.1 --- Proliferation markers --- p.8 / Chapter 1.3.3.2.2 --- Cell cycle regulators --- p.8 / Chapter 1.3.3.2.3 --- Protein controlling apoptosis --- p.10 / Chapter 1.3.4 --- Subtypes of Diffuse Large B-cell Lymphoma --- p.10 / Chapter 1.3.4.1 --- Classification method of DLBCL subtypes --- p.11 / Chapter 1.3.4.1.1 --- DNA microarray --- p.11 / Chapter 1.3.4.1.2 --- Immunohistochemistry pattern --- p.14 / Chapter 1.3.4.1.2.1 --- CD10 --- p.16 / Chapter 1.3.4.1.2.2 --- Bcl-6 --- p.16 / Chapter 1.3.4.1.2.3 --- CD138 --- p.17 / Chapter 1.3.4.1.2.4 --- MUM1/IRF4 --- p.17 / Chapter 1.3.4.2 --- Prognosis of 、DLBCL subtypes --- p.19 / Chapter 1.4 --- Interleukin 10 --- p.22 / Chapter 1.4.1 --- The IL-10 gene --- p.23 / Chapter 1.4.2 --- IL-10 promoter --- p.23 / Chapter 1.5 --- IL-10 receptor --- p.24 / Chapter 1.6 --- Cellular Signaling Pathways Regulated by IL-10 --- p.25 / Chapter 1.6.1 --- Jak/Stat Pathway --- p.25 / Chapter 1.6.2 --- Inhibition of NF B pathway --- p.26 / Chapter 1.7 --- Function of IL-10 --- p.27 / Chapter 1.7.1 --- Effects of IL-10 on immune cells in vitro --- p.27 / Chapter 1.7.2 --- Effects of IL-10 on B-cells --- p.28 / Chapter 1.8 --- IL-10 and IL-10 receptor in malignant diseases --- p.29 / Chapter 1.8.1 --- Melanoma --- p.29 / Chapter 1.8.2 --- Carcinoma --- p.30 / Chapter 1.8.3 --- Lymphoma --- p.30 / Chapter 1.9 --- Single Nucleotide Polymorphism (SNP) --- p.33 / Chapter 1.9.1 --- SNPs in cancer research --- p.34 / Chapter 1.9.1.1 --- Susceptibility to cancer and SNPs --- p.35 / Chapter 1.9.1.2 --- Outcome and SNPs --- p.35 / Chapter 1.10 --- SNP in the IL-10 promoter --- p.36 / Chapter 1.11 --- IL-10 promoter SNP in DLBCL --- p.37 / Chapter Chapter 2: --- Aims of Study --- p.39 / Chapter Chapter 3: --- Materials and Methods --- p.41 / Chapter 3.1 --- Sample Recruitment --- p.41 / Chapter 3.2 --- DNA preparation for Single Nucleotide Polymorphism (SNP) analysis --- p.41 / Chapter 3.2.1 --- Isolation of Peripheral Blood Mononuclear Cell (PBMC) from buffy coat from blood of normal control group --- p.41 / Chapter 3.2.2 --- Preparation for NHL and DLBCL samples from paraffin-embedded sections for DNA extraction --- p.42 / Chapter 3.2.3 --- DNA extraction for SNP analysis --- p.42 / Chapter 3.3 --- SNP analysis by Restriction Fragment Length Polymorphism (RFLP) --- p.43 / Chapter 3.3.1 --- Amplification of target site by PCR --- p.43 / Chapter 3.3.2 --- SNP analysis --- p.45 / Chapter 3.4 --- Determination of haplotypic frequency --- p.50 / Chapter 3.5 --- Classification of DLBCL by immunohistochemistry --- p.50 / Chapter 3.5.1 --- Staining pattern of CD10 --- p.53 / Chapter 3.5.2 --- Staining pattern of Bcl-6 --- p.54 / Chapter 3.5.3 --- Staining pattern of CD138 --- p.55 / Chapter 3.5.4 --- Staining pattern of MUM1/IRF4 --- p.56 / Chapter 3.6 --- Statistical Analysis --- p.57 / Chapter Chapter 4: --- Results --- p.58 / Chapter 4.1 --- SNPs of IL-10 promoter in normal controls --- p.58 / Chapter 4.1.1 --- Allelic Frequencies and genotype distributions --- p.58 / Chapter 4.1.2 --- Haplotypic Frequencies of normal controls --- p.58 / Chapter 4.2 --- SNP of the IL-10 promoter in non-Hodgkin's lymphomas --- p.59 / Chapter 4.2.1 --- Allelic frequencies and genotype distributions --- p.59 / Chapter 4.2.2 --- Haplolypic frequencies --- p.61 / Chapter 4.4 --- SNPs of the IL-10 promoter in DLBCL --- p.62 / Chapter 4.4.1 --- Allelic frequencies and genotype distributions --- p.62 / Chapter 4.4.2 --- Haplotypic frequencies --- p.64 / Chapter 4.5 --- SNP of the IL-10 promoter in different subtypes of DLBCL --- p.65 / Chapter 4.5.1 --- Classification of DLBCL by immunohistochemistry --- p.65 / Chapter 4.5.2 --- SNP of the IL-10 promoter in Germinal Center DLBCL (GC-DLBCL) --- p.67 / Chapter 4.5.2.1 --- Allelic frequencies and genotype distributions --- p.67 / Chapter 4.5.1.2 --- Haplotypic frequencies --- p.69 / Chapter 4.5.2 --- SNP of the IL-10 promoter in Activated Germinal Center DLBCL (AGC-DLBCL) --- p.70 / Chapter 4.5.2.1 --- Allelic frequencies and genotype distributions --- p.70 / Chapter 4.5.2.2 --- Haplotypic frequencies --- p.72 / Chapter 4.5.3 --- SNP of the IL-10 promoter in Activated non-Germinal Center DLBCL (ANGC-DLBCL) --- p.73 / Chapter 4.5.3.1 --- Allelic frequencies and genotype distributions --- p.73 / Chapter 4.5.3.2 --- Haplotypic frequencies --- p.75 / Chapter 4.5.4 --- SNP of the IL-10 promoter in Unclassified DLBCL (UC-DLBCL). --- p.76 / Chapter 4.5.4.1 --- Allelic frequencies and genotype distributions --- p.76 / Chapter 4.5.4.2 --- Haplotypic frequencies --- p.78 / Chapter 4.6 --- Summary of SNP of the IL-10 promoter in DLBCL subtypes --- p.79 / Chapter 4.7 --- Overall survival analysis --- p.80 / Chapter 4.7.1 --- Clinical data of DLBCL --- p.80 / Chapter 4.7.2 --- Cox Proportional Hazards Regression Analysis in DLBCL --- p.81 / Chapter Chapter 5: --- Discussion --- p.88 / Chapter 5.1 --- SNP for low IL-10 production in Hong Kong population --- p.88 / Chapter 5.2 --- NHL in low IL-10 production population --- p.90 / Chapter 5.2.1 --- The relationship between IL-10 and NHL --- p.90 / Chapter 5.2.2 --- Allelic frequencies and haplotype of the IL-10 promoter in NHL --- p.90 / Chapter 5.3 --- Classification of DLBCL --- p.91 / Chapter 5.3.1 --- Current prognostic analysis --- p.91 / Chapter 5.3.2 --- DLBCL subtypes distribution in Hong Kong is different from Caucasian --- p.92 / Chapter 5.4 --- IL-10 and DLBCL --- p.93 / Chapter 5.5 --- SNP of IL-10 promoter in DLBCL subtypes --- p.94 / Chapter 5.5.1 --- Allelic frequencies and haplotype of DLBCL subtypes --- p.94 / Chapter 5.5.2 --- Rare haplotypes were discovered in DLBCL --- p.94 / Chapter 5.6 --- Overall survival Analysis --- p.95 / Chapter 5.6.1 --- Univariate Cox Proportional Hazards Regression Analysis --- p.95 / Chapter 5.6.2 --- Bivariate Cox Proportional Hazards Regression Analysis --- p.96 / Chapter Chapter 6: --- Conclusion --- p.97 / References --- p.99

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 4 uppsatser.

Thesis (M.D. with Distinction in Research) -- University of Texas Southwestern Medical Center at Dallas, 2006. / Not embargoed. Vita. Bibliography: 52-62.

Orientador: Carmino Antonio de Souza / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-07T12:06:26Z (GMT). No. of bitstreams: 1 Beltrame_LuizPaulo_D.pdf: 1273755 bytes, checksum: a809e73238738768c971673f3daef900 (MD5) Previous issue date: 2006 / Resumo: As elevadas taxas de mortalidade após transplante alogênico de medula óssea (TMO) com regime de condicionamento pré-transplante mieloablativo, levou-nos a iniciar a realização destes procedimentos utilizando-se regime de condicionamento pré-transplante não-mieloablativo, para pacientes considerados de maior risco. Esta modadlidade de tratamento passou a ser oferecida para pacientes com neoplasias hematológicas que devido à idade mais avançada, e/ou presença de comorbidades, eram inelegíveis para serem submetidos a um TMO convencional, e também para aqueles que estavam sendo submetidos a um segundo TMO. Entre julho de 2001 e outubro de 2005, 26 pacientes (leucemia mielóide aguda, n=1; leucemia mielóide crônica, n=1; Linfoma de Hodgkin, n=4; Linfoma não-Hodgkin agressivo, n=6; mieloma múltiplo, n=14) receberam TMO de um doador relacionado HLA-idêntico com células progenitoras periféricas (CPP), após um condicionamento pré-TMO não-mieloablativo. O regime de condicionamento consistia de fludarabina, 30 mg/m2/dia por 3 dias, e 2 Gy de irradiação corporal total. A profilaxia da doença do enxerto-contra-hospedeiro foi feita com ciclosporina-A por 56 dias, e micofenolato mofetil por 28 dias. Dos 26 pacientes, 23 (88%) encontravam-se em progressão de doença, e 24 (92%) estavam sendo submetidos ao segundo TMO. O seguimento mediano global foi de 436 dias (3-1397 dias), e o seguimento mediano dos pacientes vivos ao término deste estudo foi de 640 dias (135-1397 dias). São apresentados também, sem qualquer finalidade comparativa, os resultados de 47 pacientes que no mesmo período e na mesma unidade, foram submetidos ao TMO com CPP após um regime de condicionamento mieloablativo. Nos pacientes que receberam TMO com regime de condicionamento não-mieloablativo, a toxicidade não-hematológica foi branda e a recuperação rápida. Infecção bacteriana foi observada em 11 pacientes (44%). O tempo mediano com contagem de neutrófilos menor que 500 células por ml de sangue foi de 6 dias, e apenas 3 pacientes (12%) atingiram contagem plaquetária abaixo de 20.000. Quimerismo hematopoiético completo foi atingido em 25 pacientes (95%), e infusão de linfócitos do doador foi necessária em 6 indivíduos, sendo em 3 devido ao estado de quimerismo misto, e em 3 devido à progressão de doença. A doença do enxerto-contra-hospedeiro (DECH) aguda graus II ou maior ocorreu em 9 pacientes (37%) e a DECH crônica extensa ocorreu em 15 (60%). Houve 12 óbitos (46%), 7 relacionados a complicações do procedimento e 5 devido a progressão de doença. A sobrevida global, sobrevida livre de progressão e tempo para progressão nestes pacientes foram respectivamente 39% (95% IC, 15-63%), 33% (95% IC, 11-55%) e 64% (95% IC, 32-96%), considerando-se um tempo de seguimento mediano de 436 dias, com variação de 3 a 1397. O TMO com regime de condicionamento pré-transplante não-mieloablativo mostrou-se factível e seguro, com redução da toxicidade e mortalidade relacionadas ao procedimento, mesmo para pacientes com neoplasias hematológicas de alto risco / Abstract: Background and Objectives. High mortality rate after allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning prompted us to offer HSCT with non-myeloablative conditioning (NST). Design and Methods. Between July, 2001 and October, 2005, 26 patients [acute myeloid leukemia, n=1; chronic myeloid leukemia, n=1; Hodgkin¿s lymphoma, n=4; aggressive non-Hodgkin¿s lymphoma n=6; multiple myeloma (MM), n=14], received peripheral NST from HLA-identical siblings. Conditioning regimen consisted of fludarabine plus 2 Gy of TBI, and GVHD prophylaxis with cyclosporine-A plus micofenolate mofetil. Eighty-eight percent were in progression of disease (PD) and 92% were undergoing their second HSCT. Results. Non-hematologic toxicities were mild and transient. Bacterial infection occurred in 44%. Median time to granulocyte recovery was six days and only 12% achieved platelets count lower than 20 x 109/L. Full donor chimerism was established in 95%. Donor lymphocyte infusion was required in 6 patients, 3 because of mixed chimerism and 3 because of PD. A-GVHD grade II or higher was observed in 37%, and extensive c-GVHD in 60%. There were 12 deaths (46%), 7 transplant related mortality and 5 related to PD. OS, PFS and time to progression (TTP) were respectively 39% (95% CI, 15-63%), 33% (95% CI, 11-55%) and 64% (95% CI, 32-96%) for the whole group. MM patients had OS, PFS and TTP of 27% (CI 95%, 0-67%), 42% (95% CI, 8-76%) and 86% (95% CI, 60-100%), respectively. Interpretation and Conclusion. This approach showed feasible and safe with reduction in transplant related toxicities, even for these high risk hematopoietic malignancies / Doutorado / Clinica Medica / Doutor em Clínica Médica

Submitted by Fabio Sobreira Campos da Costa (fabio.sobreira@ufpe.br) on 2017-07-24T14:40:58Z No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) LINFOMAS RELACIONADOS AO HIV EM ADULTOS ATENDIDOS NA REDE PÚ.pdf: 3190389 bytes, checksum: 7bff194ffad1d460a15b68dc1d8121ef (MD5) / Made available in DSpace on 2017-07-24T14:40:58Z (GMT). No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) LINFOMAS RELACIONADOS AO HIV EM ADULTOS ATENDIDOS NA REDE PÚ.pdf: 3190389 bytes, checksum: 7bff194ffad1d460a15b68dc1d8121ef (MD5) Previous issue date: 2016-08-31 / O presente estudo descreveu os linfomas associados ao vírus da imunodeficiência humana (HIV) e identificou o perfil histológico e imuno-histoquímico predominante, bem como as características clínicas gerais da população, estadiamento inicial do linfoma, terapia realizada suas complicações e o desfecho do tratamento. A pesquisa foi retrospectiva, tipo série de casos. Realizada através da coleta de dados de prontuários médicos nos serviços de arquivo de oncohematologia dos seguintes hospitais: Hospital das Clínicas da Universidade Federal de Pernambuco (HC-UFPE), Hospital de Câncer de Pernambuco (HCP), e Hospital Universitário Oswaldo Cruz (HUOC). Foram analisados 18 prontuários de pacientes infectados com HIV e/ou com aids diagnosticados com linfoma. Foram excluídos aqueles pacientes que não apresentaram estudo imuno-histoquímico do linfoma. Os dados foram alocados em tabelas próprias, que contemplaram todas as variáveis a serem estudadas. Dos 18 pacientes incluídos no estudo, 61,1% eram do sexo masculino, com idade média de 41 anos. Metade dos pacientes tiveram seu diagnóstico de infecção pelo HIV posterior ao diagnóstico do linfoma. Quanto ao estudo anatomopatológico, os tipos mais frequentes foram o linfoma não Hodgkin de células B, somando 8 casos (44,4%), e o Linfoma de Burkitt 5 (27,8%) casos. O estadiamento de Ann Arbor com modificações de Cotswolds em 14 (77,7%) pacientes estava entre III e IV. Sintomas B estiveram presentes em 11 (61,1%) pacientes, doença Bulky também em 11 (61,1%) pacientes, e comprometimento extra linfonodal em metade dos casos. Sobre o tratamento, quatro pacientes foram a óbito já na primeira linha de tratamento e dois foram refratários, enquanto que seis pacientes tiveram resposta parcial e apenas um obteve resposta completa. Entre os pacientes acompanhados na segunda linha de tratamento um foi a óbito. Dentre os que seguiram para a terceira linha de tratamento dois foram a óbito, e o único paciente que se submeteu ao quarto tratamento também evoluiu para o óbito. Em acordo com a literatura, observamos que os pacientes com diagnóstico de linfoma associado ao HIV apresentaram um estadiamento clínico inicial avançado, e evoluíram com baixas taxas de resposta à quimioterapia o que pode estar relacionado com as frequentes complicações infecciosas relacionadas ao tratamento, à não utilização do anticorpo monoclonal anti-CD20 no tratamento, ao retardo do diagnóstico, tanto do linfoma como do HIV e às baixas condições de saúde básica e de vida da população em estudo, reforçando a necessidade de melhores condições de acesso à saúde. / The present study described lymphomas associated with human immunodeficiency virus (HIV) and identified the predominant histological and immunohistochemical profile, as well as the general clinical characteristics of the population, initial lymphoma staging, therapy performed, its complications and treatment outcome. The research was of a retrospective, case series type. This was done through the collection of data from medical records in the onco-hematology archive services of the following hospitals: Clinical Hospital of the Federal University of Pernambuco (HC-UFPE), Pernambuco Cancer Hospital (HCP), and Oswaldo Cruz University Hospital (HUOC). The medical records of 18 patients were analyzed who had been infected with HIV and/or AIDS and diagnosed with lymphoma. Patients who did not present an immunohistochemical study of lymphoma were excluded. The data were allocated to separate tables, which included all the variables to be studied. Of the 18 patients included in the study, 61.1% were male, with a mean age of 41 years. Half of the patients had their diagnosis of HIV infection following the diagnosis of lymphoma. As for the anatomical and pathological study, the most frequent types were B-cell non-Hodgkin’s lymphoma, adding up to 8 cases (44.4%), and Burkitt’s lymphoma, 5 cases (27.8%). The Ann Arbor staging with Cotswolds modifications in 14 (77.7%) patients was between III and IV. B symptoms were present in 11 (61.1%) patients, bulky disease also in 11 (61.1%) patients, and extra-lymph node involvement in half of the cases. Concerning treatment, four patients died during the first line of treatment and two were refractory, while six patients had partial response and only one had a complete response. Among the patients followed in the second-line treatment, one died. Among those who went to the third-line treatment, two died, and the only patient who underwent the fourthline treatment also died. According to the literature, we observed that patients diagnosed with HIV-associated lymphoma presented an advanced initial clinical staging, and evolved with low rates of response to chemotherapy which may be related to frequent infectious complications related to treatment, non-use of the anti-CD20 monoclonal antibody in the treatment, delayed diagnosis of both lymphoma and HIV, and low basic health and life conditions of the study population, reinforcing the need for better living conditions and access to health care.